Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Click here to view

Sangamo Therapeutics Appoints Adrian Woolfson, BM., B.Ch., Ph.D., As Executive Vice President Of Research And Development